Development
Boston Scientific Corporation
BSX
$102.83
$0.400.39%
NYSE
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | 5.61% | -2.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 5.61% | -2.00% | |||
| Cost of Revenue | 4.14% | 3.93% | |||
| Gross Profit | 6.29% | -4.51% | |||
| SG&A Expenses | 11.03% | -8.27% | |||
| Depreciation & Amortization | 0.00% | -0.95% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.51% | -2.51% | |||
| Operating Income | 1.31% | 0.50% | |||
| Income Before Tax | -17.24% | 42.96% | |||
| Income Tax Expenses | -99.05% | -32.69% | |||
| Earnings from Continuing Operations | -0.20% | 86.67% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 0.00% | 86.67% | |||
| EBIT | 1.31% | 0.50% | |||
| EBITDA | 2.31% | 0.55% | |||
| EPS Basic | 0.15% | 90.64% | |||
| Normalized Basic EPS | 9.14% | 1.03% | |||
| EPS Diluted | -0.26% | 88.89% | |||
| Normalized Diluted EPS | 9.07% | 0.99% | |||
| Average Basic Shares Outstanding | 0.05% | 1.27% | |||
| Average Diluted Shares Outstanding | 0.13% | 1.29% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -1.00% | |||